Date:3/9/2010

September 12, Three Months Ended Year Ended 2002 December 31, December 31, (Inception) ------------- ------------- to December 31, 2009 2008 2009 2008 2009 ---- ---- ---- ---- ---- Revenues: Collaborative agreement $- $- $- $- $174 License revenue 22 22 88 88 441 --- --- --- --- --- Total revenues 22 22 88 88 615 Operating expenses: Research and development 8,862 17,526 47,441 79,261 216,559 General and administrative 5,923 4,602 18,177 15,651 55,999 ----- ----- ------ ------ ------ Total operating expenses 14,785 22,128 65,618 94,912 272,558 ------ ------ ------ ------ ------- Loss from operations (14,763) (22,106) (65,530) (94,824) (271,943) Other income
'/>"/>

SOURCE Orexigen Therapeutics, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)